Indo US Bio-Tech Ltd

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO. This rating was last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Indo US Bio-Tech Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its quality grade downgraded from good to average, prompting a shift in its Mojo Grade from Hold to Sell as of 19 Jan 2026. This downgrade reflects a deterioration in key business fundamentals, including returns on equity and capital employed, as well as concerns over growth consistency and leverage metrics. The stock has underperformed the broader market significantly over recent periods, raising questions about its near-term prospects.

Despite a broadly positive market environment, Indo US Bio-Tech Ltd has plunged to a fresh 52-week low of Rs 75.7 on 13 Aug 2026, marking a steep decline of over 52% from its peak of Rs 176.1 within the past year.

For the fifth consecutive session, Indo US Bio-Tech Ltd closed lower, slipping to a fresh 52-week low of Rs 79.97 on 12 Aug 2026. This decline comes amid a broader sector downturn and persistent underperformance relative to the benchmark indices.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO. This rating was last updated on 19 January 2026, reflecting a shift from the previous Hold status. However, the analysis and financial metrics discussed here represent the company’s current position as of 07 August 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and market performance.

Indo US Bio-Tech Ltd’s stock price declined to a fresh 52-week low of Rs.80.25 on 6 August 2026, marking a significant downturn amid a sustained period of underperformance. The stock has now recorded a three-day consecutive fall, cumulatively losing 3% in returns during this period, reflecting ongoing pressures within the company’s financial and market performance.

Indo US Bio-Tech Ltd’s stock price declined to a fresh 52-week low of Rs.81 on 31 July 2026, marking a significant milestone in its ongoing downward trajectory. The stock’s performance over the past year has been notably weak, reflecting a combination of subdued financial results and broader market pressures within the Other Agricultural Products sector.

For the fifth straight session, Indo US Bio-Tech Ltd closed lower, breaching its 52-week low at Rs 81.51 on 28 Jul 2026, marking a significant decline from its peak of Rs 182.80 within the last year.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 27 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

While the Sensex advanced by 0.77% today, Indo US Bio-Tech Ltd slipped to a fresh 52-week low of Rs 84.83, marking a near 50% decline over the past year. This divergence highlights the stock’s ongoing struggles amid broader market strength.

Indo US Bio-Tech Ltd’s stock price declined to a fresh 52-week low of Rs.84.96 on 24 July 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting a series of financial setbacks and technical weaknesses.

Indo US Bio-Tech Ltd’s stock price declined to a fresh 52-week low of Rs.85 on 16 Jul 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting a combination of recent financial results and technical indicators.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 16 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Indo US Bio-Tech Ltd’s stock price declined to a fresh 52-week low of Rs.85.66 on 8 July 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and the broader market, reflecting a series of financial setbacks and market pressures over the past year.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

A sharp decline in Indo US Bio-Tech Ltd has pushed the stock to a fresh 52-week low of Rs 86 on 30 Jun 2026, marking a significant 58% drop from its 52-week high of Rs 205.1. This downturn comes amid a backdrop of weakening quarterly financials and diminishing promoter confidence, even as the broader agricultural sector has shown resilience.